{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:04:45Z","timestamp":1785470685564,"version":"3.56.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T00:00:00Z","timestamp":1656806400000},"content-version":"am","delay-in-days":275,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jbspin.2021.105208","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T21:20:55Z","timestamp":1622928055000},"page":"105208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience"],"prefix":"10.1016","volume":"88","author":[{"given":"Justine","family":"Bacchetta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Rothenbuhler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3562-6973","authenticated-orcid":false,"given":"Iva","family":"Gueorguieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kamenicky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0941-8951","authenticated-orcid":false,"given":"Jean-Pierre","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Briot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2021.105208_bib0180","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00590-014-1496-y","article-title":"Hypophosphatemic rickets: etiology, clinical features, and treatment","volume":"25","author":"Pavone","year":"2015","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"10.1016\/j.jbspin.2021.105208_bib0185","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1359\/jbmr.090509","article-title":"Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets\/osteomalacia","volume":"24","author":"Aono","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbspin.2021.105208_bib0190","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","article-title":"Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data, and treatment","volume":"62","author":"Endo","year":"2015","journal-title":"Endocr J"},{"key":"10.1016\/j.jbspin.2021.105208_bib0195","unstructured":"Orphanet. [Available from: https:\/\/www.orpha.net\/consor\/cgi-bin\/Disease_Search.php?lng=FR&data_id=11911&Disease_Disease_Search_diseaseType=ORPHA&Disease_Disease_Search_diseaseGroup=89936&Disease(s)\/group%20of%20diseases=XLH&title=XLH&search=Disease_Search_Simple]."},{"key":"10.1016\/j.jbspin.2021.105208_bib0200","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.bone.2013.01.046","article-title":"Osteocyte regulation of phosphate homeostasis and bone mineralization underlies the pathophysiology of the heritable disorders of rickets and osteomalacia","volume":"54","author":"Feng","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.jbspin.2021.105208_bib0205","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-08-0818","article-title":"Incidence and prevalence of nutritional and hereditary rickets in southern Denmark","volume":"160","author":"Beck-Nielsen","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jbspin.2021.105208_bib0210","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jbspin.2021.105208_bib0215","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/EJE-15-0661","article-title":"Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms","volume":"174","author":"Che","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jbspin.2021.105208_bib0220","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jbspin.2019.01.012","article-title":"X-linked hypophosphatemia: management and treatment prospects","volume":"86","author":"Lambert","year":"2019","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2021.105208_bib0225","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00467-011-2046-z","article-title":"Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment","volume":"27","author":"Quinlan","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jbspin.2021.105208_bib0230","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1210\/jc.2003-030036","article-title":"Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets","volume":"88","author":"Makitie","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jbspin.2021.105208_bib0235","doi-asserted-by":"crossref","first-page":"153892","DOI":"10.1016\/j.metabol.2019.03.009","article-title":"Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH)","volume":"103S","author":"Rothenbuhler","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.jbspin.2021.105208_bib0240","doi-asserted-by":"crossref","first-page":"146","DOI":"10.5395\/rde.2017.42.2.146","article-title":"Dental management of patients with X-linked hypophosphatemia","volume":"42","author":"Lee","year":"2017","journal-title":"Restor Dent Endod"},{"key":"10.1016\/j.jbspin.2021.105208_bib0245","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bone.2012.11.009","article-title":"Osteopetrosis, osteopetrorickets and hypophosphatemic rickets differentially affect dentin and enamel mineralization","volume":"53","author":"Koehne","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.jbspin.2021.105208_bib0250","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1515\/cclm-2020-0460","article-title":"FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference","volume":"58","author":"Piketty","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jbspin.2021.105208_bib0255","series-title":"Protocole National de Diagnostic et de Soins (PNDS)","year":"2018"},{"key":"10.1016\/j.jbspin.2021.105208_bib0260","series-title":"GeneReviews\u00ae [Internet]","article-title":"X-Linked hypophosphatemia","author":"Ruppe","year":"1993"},{"key":"10.1016\/j.jbspin.2021.105208_bib0265","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","article-title":"The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey","volume":"3","author":"Skrinar","year":"2019","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.jbspin.2021.105208_bib0270","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM197209072871003","article-title":"Use of phosphate and vitamin D to prevent dwarfism and rickets in X-linked hypophosphatemia","volume":"287","author":"Glorieux","year":"1972","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2021.105208_bib0275","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","journal-title":"Endocr Connect"},{"key":"10.1016\/j.jbspin.2021.105208_bib0280","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ando.2020.12.005","article-title":"Rare diseases of phosphate and calcium metabolism: crossing glances between nephrology and endocrinology","volume":"82","author":"Mosca","year":"2021","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.jbspin.2021.105208_bib0285","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s12325-019-01193-0","article-title":"Exploring the burden of X-Linked hypophosphataemia: an opportunistic qualitative study of patient statements generated during a technology appraisal","volume":"37","author":"Ferizovic","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.jbspin.2021.105208_bib0290","unstructured":"SmPC. [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/crysvita-epar-product-information_en.pdf]."},{"key":"10.1016\/j.jbspin.2021.105208_bib0295","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2021.105208_bib0300","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1\u20134 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jbspin.2021.105208_bib0305","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s40267-018-0560-9","article-title":"Burosumab in X-linked hypophosphatemia: a profile of its use in the USA","volume":"34","author":"Lyseng-Williamson","year":"2018","journal-title":"Drugs Ther Perspect"},{"key":"10.1016\/j.jbspin.2021.105208_bib0310","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2021.105208_bib0315","unstructured":"Commission de la transparence. Avis 23 janvier 2019. [Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2019-01\/crysvita_pic_ins_avis3_ct16912.pdf]."},{"key":"10.1016\/j.jbspin.2021.105208_bib0320","doi-asserted-by":"crossref","first-page":"154049","DOI":"10.1016\/j.metabol.2019.154049","article-title":"Management of X-linked hypophosphatemia in adults","volume":"103S","author":"Lecoq","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.jbspin.2021.105208_bib0325","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A Randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbspin.2021.105208_bib0330","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jbspin.2021.105208_bib0335","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s00223-020-00665-8","article-title":"Hyperphosphatemia and chronic kidney disease: a major daily concern both in adults and in children","volume":"108","author":"Bacchetta","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jbspin.2021.105208_bib0340","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00008480-200108000-00015","article-title":"Ectopic cardiac calcification associated with hyperparathyroidism in a boy with hypophosphatemic rickets","volume":"13","author":"Moltz","year":"2001","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.jbspin.2021.105208_bib0345","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/ocr.12120","article-title":"A radiological study on intra- and extra-cranial calcifications in adults with X-linked hypophosphatemia and associations with other mineralizing enthesopathies and childhood medical treatment","volume":"19","author":"Gjorup","year":"2016","journal-title":"Orthod Craniofac Res"},{"key":"10.1016\/j.jbspin.2021.105208_bib0350","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s10354-019-00732-2","article-title":"Multidisciplinary patient care in X-linked hypophosphatemic rickets: one challenge, many perspectives","volume":"170","author":"Raimann","year":"2020","journal-title":"Wien Med Wochenschr"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X21000804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X21000804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:28:14Z","timestamp":1761150494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X21000804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1297319X21000804"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2021.105208","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2021.105208","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105208"}}